In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioVitrum/Amgen: A Sign of Early-Stage Deals to Come

Executive Summary

Biovitrum's record-breaking deal with Amgen--the largest licensing transaction by a European Biotech player to date-secures for Biovitrum the financial and strategic means to help it become a fully integrated biopharmaceutical company. The deal is also strategically important to Amgen, giving the company a way into the primary care segment. But the price and risk are high: there's no clinical proof of efficacy on the compound and there's no competitive compound on the market, or even in late-stage clinical trials, proving the value of the target. Thus the broader implication for the industry: as the costs of late-stage licensing become prohibitive-and the compounds themselves unavailable-in-licensers are increasingly looking to earlier-stage products to bolster their pipelines, with deal prices, and risks, rising correspondingly.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts